Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). MASH is a growing public health concern due to its increasing prevalence, driven by factors like obesity, type 2 diabetes, and metabolic syndrome. MASH can progress to advanced liver scarring (fibrosis) and cirrhosis, increasing the risk of liver cancer and …Read More >

Gout is a common type of inflammatory arthritis caused by elevated uric acid levels in the blood. When uric acid levels are too high, monosodium urate (MSU) crystals can form in the body, especially in and around joints. These MSU crystals are sharp and can cause inflammation when they are deposited in the joints, leading …Read More >

Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders. Advances in metabolic research have positioned glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising therapeutic option for MASH, extending their use beyond diabetes and obesity management. This article examines the …Read More >

Kidney diseases are complex conditions caused by a variety of factors, including autoimmune diseases, metabolic disorders, infections, drug side effects, and genetics. Kidney diseases can lead to a range of complications, including kidney failure, anemia, electrolyte imbalances, and nerve damage, thereby affecting the quality of life. To drive breakthroughs in this critical field, WuXi AppTec …Read More >

Women’s health care is crucial not only for the well-being of individual women but also for the health and prosperity of families and communities. Despite significant medical advancements, there remains a concerning gap in the availability of effective drugs for common women-related diseases such as endometriosis, menopause syndromes, polycystic ovary syndrome (PCOS), and various forms …Read More >

Metabolic diseases are considered to arise from multiple factors, including genetics, diet, age, and environmental factors, and often affect various organs throughout the body.  No single cause is solely responsible for these disorders. To support research in this area, WuXi AppTec offers a comprehensive platform of in vitro and in vivo services.  Our capabilities include …Read More >

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was …Read More >

Casein kinase 2-interacting protein-1 (CKIP-1) performs a critical negative role in the regulation of bone formation. Accumulated evidence strongly supports CKIP-1 as an attractive therapeutic target in osteoporosis.  As a scaffold protein lacking enzymatic activity, CKIP-1 seems to be an undruggable target, and the development of selective small molecule inhibitors targeting CKIP-1 has proven to …Read More >

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However, because of the continued need for injectable administration, many GLP-1 agonists face compliance challenges. To improve the design and production of GLP-1 receptor biased agonists with enhanced druggability, a novel small molecule, designated SAL0112, was …Read More >